JAN 13, 2020 7:47 AM PST

Vaccine Against Alzheimer's to Hit Clinical Trials

WRITTEN BY: Annie Lennon

Currently Alzheimer’s disease is thought to affect around 50 million people around the world, with this figure doubling every year. Currently with no cure and no guaranteed preventative strategy, within just a couple years, a vaccination to combat its primary causes may begin human trials. 

The development of a vaccine comes after the failure of many drugs designed to reduce the build-up of amyloid protein and tau in the brain- thought to be the two primary causes of Alzheimer’s-related neurodegeneration. Whereas previous attempts to focus on reducing tau and amyloid accumulation separately have largely failed, researchers now believe that focusing on both simultaneously may hold more promise- as there is growing evidence suggesting a synergistic relationship between the two in driving neurodegeneration. 

Moreover, as most treatments targeting these protein build-ups have been more reactive than proactive, scientists from the Institute for Molecular Medicine and the University of California, Irvine, decided to work on vaccine-based measures to simultaneously prevent both of these toxic proteins from accumulating in the first place. 

For their study, they combined two existing vaccines, known as AV-1959R and AV-1980R, designed respectively to target amyloid and tau protein build-ups. The vaccine itself was delivered via a novel adjuvant known as Advax, a delivery method designed to improve the efficacy of any therapy. 

Nikolai Petrovsky, one of the scientists being Advax and a researcher at Australia’s Flinders University, said, “Our approach is looking to cover all the bases and get past previous roadblocks in finding a therapy to slow the accumulation of Aβ/tau molecules and delay AD progression in a rising number of people around the world.

Aiming for the vaccine to hit human clinical trials within two years, Petrovsky continued, “In the animal models, we can both use it to prevent the development of memory loss by giving it before the animal starts to get these build-ups of proteins...But we can also show that even when we give it after the animals have proteins, we can actually get rid of the abnormal proteins.”

"It's an exciting time to be starting the new decade – hopefully this is the breakthrough of the next decade if we can get it to work in human trials.”


 

Sources: New Atlas, EPM Magazine and Study Finds

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
APR 25, 2022
Microbiology
How a Serious Infection Can Cause Mood Disorders
APR 25, 2022
How a Serious Infection Can Cause Mood Disorders
When a pathogen invades the body, the immune system has to mount a response, which involves inflammation. But inflammati ...
MAY 12, 2022
Drug Discovery & Development
Gut Bacteria Composition Predicts Resposnse to Statins
MAY 12, 2022
Gut Bacteria Composition Predicts Resposnse to Statins
The composition of the gut microbiome is predictive of patient responses to statins. The corresponding study was publish ...
MAY 13, 2022
Health & Medicine
Increased Mental Health Risks Linked to High Potency Cannabis Concentrates
MAY 13, 2022
Increased Mental Health Risks Linked to High Potency Cannabis Concentrates
As more states legalize cannabis for medical and recreational purposes, the association between excessive cannabis consu ...
JUN 21, 2022
Cell & Molecular Biology
From sample collection straight to RT-qPCR
JUN 21, 2022
From sample collection straight to RT-qPCR
Skip the nucleic acid purification step in your cancer detection workflow. Learn more about how Thermo Fisher Scientific ...
JUN 02, 2022
Coronavirus
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
JUN 02, 2022
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
It has been clear for some time that loneliness and social isolation can lead to increased risks for adverse h ...
JUN 20, 2022
Health & Medicine
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
JUN 20, 2022
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
The New England Journal of Medicine published results from a small study by researchers at New York’s Memorial Slo ...
Loading Comments...